A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Summary

An open-label, multi-center, Phase 1/2 study to determine the safety, tolerability, and feasibility of dosing adult patients with mCRPC with genetically modified autologous T-cells (TmPSMA-02) engineered to express a CAR capable of recognizing the tumor antigen prostate-specific membrane antigen (PSMA) and activating the T-cell.

Timeline

Start

2022-09-06

Primary completion

2023-05-03

Completion

2023-05-03

Outcome

Outcome not reported

Stopped: “Study was stopped Sponsor discretion. No patients were dosed.”

Drugs

Indications